Oral tofacitinib for psoriasis: what happens with interrupted treatment?

E-ISSN： 1365-2133|172|5|1194-1195

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.172, Iss.5, 2015-05, pp. : 1194-1195

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 949-961

John Wiley & Sons Inc

Access to resources Recommend Favorite

An Open Trial of Oral Macrolide Treatment for Psoriasis Vulgaris

THE JOURNAL OF DERMATOLOGY, Vol. 27, Iss. 8, 2000-08 ,pp. : 508-512

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Psoriasis Vulgaris with Oral 1α,25‐Dihydroxyvitamin D3

THE JOURNAL OF DERMATOLOGY, Vol. 14, Iss. 1, 1987-02 ,pp. : 59-62

John Wiley & Sons Inc

Access to resources Recommend Favorite

Oral psoriasis: an atypical case

By Curien Rémi Maschino François Guillet Julie Bravetti Pierre

Médecine Buccale - Chirurgie Buccale, Vol. 18, Iss. 1, 2012-03 ,pp. : 45-47

Edp Sciences

Access to resources Recommend Favorite

Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class?

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 539-540

John Wiley & Sons Inc

Access to resources Recommend Favorite